Literature DB >> 22696652

Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus.

Mridula Rani1, Meagan Bolles, Eric F Donaldson, Thomas Van Blarcom, Ralph Baric, Brent Iverson, George Georgiou.   

Abstract

Even though the effect of antibody affinity on neutralization potency is well documented, surprisingly, its impact on neutralization breadth and escape has not been systematically determined. Here, random mutagenesis and DNA shuffling of the single-chain variable fragment of the neutralizing antibody 80R followed by bacterial display screening using anchored periplasmic expression (APEx) were used to generate a number of higher-affinity variants of the severe acute respiratory syndrome coronavirus (SARS-CoV)-neutralizing antibody 80R with equilibrium dissociation constants (K(D)) as low as 37 pM, a >270-fold improvement relative to that of the parental 80R single-chain variable fragment (scFv). As expected, antigen affinity was shown to correlate directly with neutralization potency toward the icUrbani strain of SARS-CoV. Additionally, the highest-affinity antibody fragment displayed 10-fold-increased broad neutralization in vitro and completely protected against several SARS-CoV strains containing substitutions associated with antibody escape. Importantly, higher affinity also led to the suppression of viral escape mutants in vitro. Escape from the highest-affinity variant required reduced selective pressure and multiple substitutions in the binding epitope. Collectively, these results support the hypothesis that engineered antibodies with picomolar dissociation constants for a neutralizing epitope can confer escape-resistant protection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22696652      PMCID: PMC3416138          DOI: 10.1128/JVI.00233-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementarity-determining region of antibodies triggered by HIV-1 infection.

Authors:  J L Torán; L Sánchez-Pulido; L Kremer; G del Real; A Valencia; C Martínez-A
Journal:  Eur J Immunol       Date:  2001-01       Impact factor: 5.532

Review 2.  Motavizumab.

Authors:  Oya Cingoz
Journal:  MAbs       Date:  2009-09-10       Impact factor: 5.857

3.  Improved expression characteristics of single-chain Fv fragments when fused downstream of the Escherichia coli maltose-binding protein or upstream of a single immunoglobulin-constant domain.

Authors:  A Hayhurst
Journal:  Protein Expr Purif       Date:  2000-02       Impact factor: 1.650

4.  Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.

Authors:  Qing Zhu; Josie M McAuliffe; Nita K Patel; Frances J Palmer-Hill; Chin-fen Yang; Brandon Liang; Lan Su; Wei Zhu; Leslie Wachter; Susan Wilson; Randall S MacGill; Subramaniam Krishnan; Michael P McCarthy; Genevieve A Losonsky; JoAnn A Suzich
Journal:  J Infect Dis       Date:  2011-01-05       Impact factor: 5.226

5.  Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.

Authors:  Timothy Sheahan; Alan Whitmore; Kristin Long; Martin Ferris; Barry Rockx; William Funkhouser; Eric Donaldson; Lisa Gralinski; Martha Collier; Mark Heise; Nancy Davis; Robert Johnston; Ralph S Baric
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

6.  Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.

Authors:  Mei-Yun Zhang; Andrew Rosa Borges; Roger G Ptak; Yanping Wang; Antony S Dimitrov; S Munir Alam; Lindsay Wieczorek; Peter Bouma; Timothy Fouts; Shibo Jiang; Victoria R Polonis; Barton F Haynes; Gerald V Quinnan; David C Montefiori; Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-05-05       Impact factor: 5.857

7.  Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus.

Authors:  Barry Rockx; Eric Donaldson; Matthew Frieman; Timothy Sheahan; Davide Corti; Antonio Lanzavecchia; Ralph S Baric
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

8.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

9.  On the mechanisms of bananin activity against severe acute respiratory syndrome coronavirus.

Authors:  Zai Wang; Jian-Dong Huang; Kin-Ling Wong; Pei-Gang Wang; Hao-Jie Zhang; Julian A Tanner; Ottavia Spiga; Andrea Bernini; Bo-Jian Zheng; Neri Niccolai
Journal:  FEBS J       Date:  2010-12-06       Impact factor: 5.542

Review 10.  The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Authors:  Lanying Du; Yuxian He; Yusen Zhou; Shuwen Liu; Bo-Jian Zheng; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2009-02-09       Impact factor: 60.633

View more
  15 in total

1.  Severe acute respiratory syndrome: a vanished evil?

Authors:  Wei-Jie Guan; Xue-Yan Zheng; Guang-Qiao Zeng; Nan-Shan Zhong
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.

Authors:  Jianhua Sui; Meagan Deming; Barry Rockx; Robert C Liddington; Quan Karen Zhu; Ralph S Baric; Wayne A Marasco
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

3.  Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.

Authors:  M L Azoitei; Y A Ban; O Kalyuzhny; J Guenaga; A Schroeter; J Porter; R Wyatt; William R Schief
Journal:  Proteins       Date:  2014-07-31

4.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.

Authors:  Xian-Chun Tang; Sudhakar S Agnihothram; Yongjun Jiao; Jeremy Stanhope; Rachel L Graham; Eric C Peterson; Yuval Avnir; Aimee St Clair Tallarico; Jared Sheehan; Quan Zhu; Ralph S Baric; Wayne A Marasco
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

5.  Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.

Authors:  John T Bates; Christopher J Keefer; Thomas J Utley; Bruno E Correia; William R Schief; James E Crowe
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

6.  Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

Authors:  Annalisa Meola; Alexander W Tarr; Patrick England; Luke W Meredith; C Patrick McClure; Steven K H Foung; Jane A McKeating; Jonathan K Ball; Felix A Rey; Thomas Krey
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

7.  Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.

Authors:  Sonia Budroni; Francesca Buricchi; Andrea Cavallone; Patricia Bourguignon; Magalie Caubet; Vincent Dewar; Ugo D'Oro; Oretta Finco; Nathalie Garçon; Mohamed El Idrissi; Michel Janssens; Geert Leroux-Roels; Arnaud Marchant; Tino Schwarz; Pierre Van Damme; Gianfranco Volpini; Robbert van der Most; Arnaud M Didierlaurent; Wivine Burny
Journal:  NPJ Vaccines       Date:  2021-05-21       Impact factor: 7.344

8.  A dual-mode surface display system for the maturation and production of monoclonal antibodies in glyco-engineered Pichia pastoris.

Authors:  Hussam H Shaheen; Bianka Prinz; Ming-Tang Chen; Tej Pavoor; Song Lin; Nga Rewa Houston-Cummings; Renee Moore; Terrance A Stadheim; Dongxing Zha
Journal:  PLoS One       Date:  2013-07-10       Impact factor: 3.240

9.  Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.

Authors:  Jean-Louis Excler; Christopher J Delvecchio; Ryan E Wiley; Marni Williams; In-Kyu Yoon; Kayvon Modjarrad; Mohamed Boujelal; Vasee S Moorthy; Ahmad Salah Hersi; Jerome H Kim
Journal:  Emerg Infect Dis       Date:  2016-08       Impact factor: 6.883

10.  Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.

Authors:  Sudhakar Agnihothram; Vineet D Menachery; Boyd L Yount; Lisa C Lindesmith; Trevor Scobey; Alan Whitmore; Alexandra Schäfer; Mark T Heise; Ralph S Baric
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.